{"source_content":"www.swsc.com.cn2020年H1血制品批签发：多数品种增长较好西南证券研究发展中心2020年7月分析师：杜向阳执业证号：S1250520030002电话：021-68416017邮箱：duxy@swsc.com.cn分品种来看：人血白蛋白：2020H1人白批签发量超3000万瓶，同比增长35%。其中Q1增长83%，主要受去年上海新兴事件影响，导致同期低基数。2020H1进口2029万瓶(+58%)，占整体66%；国产1051万瓶(+6%)，占整体34%。免疫球蛋白：2020H1静丙批签发量为705万瓶，同比增长50%。其他品种如狂免566万瓶(+21%)、破免293万瓶(+12%)；免疫球蛋白174万瓶(+258%)、乙免116万瓶(+7%)。凝血因子类：PCC81万瓶(+111%)、凝血因子VIII101万瓶(+43%)。纤原62万瓶(+38%)。分公司来看：华兰生物：2020H1人白120万瓶(+9%)，破免、PCC同比增长超100%。双林生物：2020H1人白43万瓶(+9%)，静丙38万瓶(+233%)。卫光生物：2020H1人白54万瓶(+13%)，静丙35万瓶(+45%)，狂免110万瓶(+137%)。天坛生物：2020H1人白236万瓶(+7%)；静丙、狂免、乙免等同比增长超30%。博雅生物：2020H1人白58万瓶(+75%)，静丙41万瓶(+62%)。投资建议：2020H1多数品种实现批签发量快速增长。新兴事件过后，监管趋严，同时今年疫情导致上半年采浆减少，下半年供给有望趋紧，中长期来看，集中度有望提升，整体未来发展值得看好。重点推荐华兰生物、双林生物、卫光生物、天坛生物等，建议关注博雅生物。2020年H1血制品批签发：多数品种增长较好风险提示：政策变化风险；企业产品质量风险；新品种研发不及预期。证券代码证券名称股价EPSPE2020E2021E2022E2020E2021E2022E002007华兰生物48.641.181.371.58413631000403双林生物75.972.112.944.11362618600161卫光生物66.921.942.352.8352924600161天坛生物46.580.700.841.00675547300294博雅生物52.281.461.842.26362924估值日期：2020年7月10日数据来源：wind，西南证券整理12数据来源：中检院，西南证券整理，截至2020.07.01分品种批签发数据汇总2020H1血制品各品种批签发情况血制品名称国产/进口规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-6月2020年1-6月2019年4-6月2020年4-6月2019年6月2020年6月人血白蛋白（规格换算/10g）进口1283.502029.3958.11%898.47954.286.21%415.67212.41-48.90%国产979.131025.344.72%489.21486.75-0.50%166.07132.96-19.94%合计2262.643054.7335.01%1387.681441.033.84%581.74345.37-40.63%免疫球蛋白静注人免疫球蛋白（规格换算/10g）合计469.11705.1350.31%237.29249.265.04%58.7887.9849.69%狂犬病免疫球蛋白（规格换算/200IU）合计466.24566.0621.41%189.41306.0261.56%93.32122.3431.09%破伤风免疫球蛋白（规格换算/250IU）合计261.27293.1112.18%135.27131.03-3.14%30.1018.68-37.95%免疫球蛋白（规格换算/150mg）合计48.53173.78258.11%0.0050.63上年同期无批签发0.0018.76上年同期无批签发乙肝免疫球蛋白（规格换算/100IU）合计108.09115.877.20%94.8875.57-20.35%27.6844.0659.20%冻干静注人免疫球蛋白（规格换算/2.5g）合计19.4054.61181.57%10.9415.6142.59%6.404.37-31.63%静注乙型肝炎人免疫球蛋白（规格换算/2000IU）四川远大1.075.80441.57%0.685.08649.53%0.000.00上年同期无批签发凝血因子类凝血因子VIII（规格换算/200IU）合计70.65100.9042.81%33.8540.7520.38%9.6016.8775.83%人凝血酶原复合物（规格换算/200IU）合计38.3080.90111.22%24.9644.8979.86%8.5219.36127.27%纤维蛋白原（规格换算/0.5g）合计45.3962.4437.59%15.4334.91126.19%3.8913.27241.06%分公司来看：华兰生物：2020H1获批8种血制品。人血白蛋白获批120万瓶(+9%)，破免、PCC同比增长超100%。整体批签发量较去年同期稳步增长。双林生物：2020H1获批4种血制品。人血白蛋白获批43万瓶(+9%)，静丙获批38万瓶(+233%)，破免增长36%。卫光生物：2020H1获批4种血制品。人血白蛋白获批54万瓶(+13%)，静丙获批35万瓶(+45%)，狂免获批110万瓶(+137%)。天坛生物：2020H1获批5种血制品。人血白蛋白获批236万瓶(+7%)；乙肝免疫球蛋白、狂免、静丙同比增长超30%，免疫球蛋白整体快速增长。博雅生物：2020H1获批6种血制品。人血白蛋白获批58万瓶(+75%)，静丙获批41万瓶(+62%)，狂免同比增长超50%。公司新增免疫球蛋白与乙肝免疫球蛋白两种血制品批签发。上海莱士：2020H1获批9种血制品，批签发量较去年同期快速增长。人血白蛋白获批147万瓶，(+39%)，静丙获批113万瓶(+388%)，凝血因子类同比增长超300%，其中纤原同比增长高达1066%。博晖创新(300318)：2020H1冻干静丙同比增长688%，人血白蛋白增长55%。泰邦生物(CBPO)：2020H1PCC、狂免同比增长超100%。2020H1血制品公司批签发情况31.人血白蛋白：过去十年批签发快速增长，进口占比六成以上2.静注人免疫球蛋白：新冠疫情期间静丙批签发量快速增长3.免疫球蛋白：近年批签发明显回暖，新进入者带动批签发显著提升4.狂犬病免疫球蛋白：2020H1批签发回暖，泰邦控股等批签发快速增长5.破伤风免疫球蛋白：2020H1华兰生物等批签发快速增长6.乙肝免疫球蛋白：2020H1批签发回暖，卫光生物等批签发快速增长7.凝血酶原复合物：近几年批签发较平稳，2020H1批签发快速增长8.凝血因子Ⅷ：近几年批签发稳步增长，上海莱士增速明显9.纤维蛋白原：近几年批签发略有下滑，2020年二季度同比快速增长国内血制品各品种批签发摘要41.人血白蛋白：过去十年批签发快速增长，进口占比六成以上进口及国产人血白蛋白历年批签发情况(万瓶，按年份)数据来源：药智网，中检院，西南证券整理从批签发来看，2007-2019年人血白蛋白批签发复合年均增长率(CAGR)为+22%。2019年，国内人血白蛋白批签发量为5285万瓶(+11%)(换算成10g/瓶，后同)，其中国产批签发为2120万瓶(+13%)，占比40%，进口批签发为3165万瓶(+11%)，占比60%。2020H1，国内人血白蛋白批签发量为3081万瓶(+35%)，其中进口人血白蛋白批签发量为2029万瓶(占比66%)。Q1人血白蛋白批签发量为1612万瓶(+83%)，主要受19年初上海新兴事件以及部分外资企业GMP到期重新认证等因素影响，进口人血白蛋白批签发量下滑明显，整体批签发量较少。Q2人血白蛋白批签发量为1469万瓶(+5%)，同比稳健增长。进口与国产人血白蛋白历年批签发份额占比0%10%20%30%40%50%60%70%80%90%100%0100020003000400050006000人血白蛋白批签发量（万瓶）人血白蛋白同比增长0%10%20%30%40%50%60%70%80%90%100%进口人血白蛋白批签发国产人血白蛋白批签发5人血白蛋白分季度批签发进口与国产占比1.人血白蛋白：过去十年批签发快速增长，进口占比六成以上近年来，随着人血白蛋白临床需求的不断增加，人血白蛋白的进口量不断增大。2014年至今，进口人血白蛋白市场份额基本超过六成以上，除去2019年Q1受部分外资企业GMP到期重新认证影响，其它季度进口人血白蛋白市场份额均多过国产人血白蛋白。2020H1进口人血白蛋白批签发份额为66%，批签发总量前4位的进口厂商分别为杰特贝林(CSL)、基立福(Grifols)、百特(Baxter)和奥克特珐玛(Octa-pharma)。2020H1国产人血白蛋白批签发份额为34%，前4位的厂商是分别是天坛生物获批236万瓶(市场份额8%)、泰邦生物获批164万瓶(市场份额5%)、上海莱士152万瓶(市场份额5%)和华兰生物120万瓶(市场份额4%)等。上海莱士、双林生物、博雅生物、博晖创新等公司批签发量同比快速增长。数据来源：药智网，中检院，西南证券整理2020H1人血白蛋白批签发情况(万瓶)杰特贝林,757.6,25%百特,473.0,15%奥科特法玛,419.9,14%基立福,337.1,11%天坛生物,236.1,8%泰邦控股,164.4,5%[类别名称][值][百分比][类别名称][值][百分比]0%10%20%30%40%50%60%70%80%90%100%进口人血白蛋白批签发国产人血白蛋白批签发6进口人血白蛋白历年批签发情况(万瓶，按年份)进口人血白蛋白批签发量2007年-2019年CAGR(年均复合增长率)为+34%，过去十年进口人血白蛋白每年的市场份额占比超过50%以上，2010-2019年批签发量保持年化10%以上的稳健增长。进口人血白蛋白批签发主要集中在几家大型的血制品企业，批签发总量前4位的进口厂商分别为杰特贝林(CSL)、基立福(Grifols)、百特(Baxter)和奥克特珐玛(Octa-pharma)。2020H1进口人血白蛋白批签发量为2029万瓶(+58%)，市场份额66%。2019H1基数较低，主要原因是19年Q1部分外资企业GMP到期，需要重新认证。2020Q1进口人血白蛋白批签发量为1069万瓶(+175%)；Q2进口批签发量为961万瓶(+7%)。2020H1进口人血白蛋白批签发情况(万瓶)CSL,758,45%百特国际,473,28%基立福,337,20%Biotest,86,5%奥克特珐玛,22,1%1.1进口人血白蛋白：2020H1批签发量同比快速增长数据来源：药智网，中检院，西南证券整理0%50%100%150%200%250%0500100015002000250030003500进口人血白蛋白批签发（万瓶）进口人血白蛋白同比增长71.1进口人血白蛋白：2020H1批签发量同比快速增长人血白蛋白历年进口外国厂商批签发量占比人血白蛋白过去三年分季度进口外国厂商批签发量占比2007-2020H1，进口人血白蛋白批签发主要集中在几家大型的血制品企业。其中，批签发量占比最高的国外厂商是杰特贝林(CSL)，整体占到40%左右。基立福(Grifols)、百特(Baxter)与奥克特珐玛(Octa-pharma)整体批签发量占比也在20%左右，Biotest整体批签发占比1%。数据来源：药智网，中检院，西南证券整理0%10%20%30%40%50%60%70%80%90%100%杰特贝林基立福百特奥克特珐玛绿十字Biotest0%10%20%30%40%50%60%70%80%90%100%杰特贝林基立福百特奥克特珐玛绿十字Biotest8企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2BaxaltaUSInc.224.9082.92-63.13%178.8240.36-77.43%BaxterAG192.44303.9057.92%124.28113.97-8.29%BaxterManufacturingS.p.A.27.6886.22211.44%27.6861.11120.73%BiotestPharmaGmbH0.0019.90上年同期无批签发0.002.96上年同期无批签发CSLBehringAG(瑞士杰特贝林生物制品有限公司)306.09581.1889.87%202.32307.6752.07%CSLBehringGmbH(德国杰特贝林生物制品有限公司)108.74157.0844.46%81.0496.4919.06%CSLBehringL.L.C.(美国杰特贝林生物制品有限公司)89.4219.35-78.36%7.5919.35155.05%GrifolsBiologicalsInc.(美国基立福公司)82.52199.94142.29%82.5263.37-23.21%InstitutoGrifols,S.A.(西班牙基立福公司)118.38137.1315.84%69.0617.19-75.11%OctapharmaPharmazeutikaProduktionsGmbH(奥克特珐玛药剂生产有限公司)38.61242.67528.58%38.61132.84244.07%奥克特珐玛AB公司(瑞典)76.77177.19130.82%76.7798.9828.93%绿十字株式会社/韩国17.9521.9022.04%9.770.00-100.00%进口总计1283.502029.3958.11%898.47954.286.21%1.1进口人血白蛋白：2020H1批签发量同比快速增长进口人血白蛋白2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理9国产人血白蛋白批签发量2007-2019年CAGR为+16%，近五年保持10%以上稳定增长。2020H1国产批签发量为1051万瓶(+6%)，占国内人血白蛋白批签发的34%。其中Q1国产人血白蛋白批签发量为500万瓶(+10%)，Q2批签发量为543万瓶(+3%)。2020Q1国产人血白蛋白同比快速增长，主要系19年初上海新兴事件影响，人血白蛋白批签发量较低。2020H1，总共13家国产企业获批人血白蛋白。其中，批签发量占比最高的分别是天坛生物236万瓶(占国产22%)、泰邦生物164万瓶(占国产16%)、上海莱士152万瓶(占国产14%)和华兰生物120万瓶(占国产11%)等。上海莱士，博雅生物，博晖创新，双林生物等公司同比快速增长。1.2国产人血白蛋白：2020H1批签发量同比增长6%国产白蛋白历年批签发情况(万瓶，按年份)2020H1国产白蛋白批签发情况(万瓶)0%5%10%15%20%25%30%35%40%45%05001000150020002500国产白蛋白批签发国产白蛋白同比增长天坛生物,236,22%泰邦生物,164,16%上海莱士,152,14%华兰生物,120,11%四川远大,81,8%博雅生物,80,8%卫光生物,54,5%双林生物,43,4%数据来源：药智网，中检院，西南证券整理10人血白蛋白过去三年分季度国产企业批签发量占比1.2国产人血白蛋白：2020H1批签发量同比增长6%人血白蛋白历年国产企业批签发量占比2007年-2020H1有超过10家国产企业获批人血白蛋白。国产人血白蛋白批签发份额比较分散，批签发量较高的企业主要是天坛生物、泰邦生物、上海莱士与华兰生物。这四家公司合计占到国产人血白蛋白市场份额64%，前八家占国产比例88%。0%10%20%30%40%50%60%70%80%90%100%泰邦生物天坛生物上海莱士华兰生物四川远大山西康宝双林生物卫光生物博雅生物南岳生物博晖创新派斯菲科绿十字新疆能源生物0%20%40%60%80%100%天坛生物泰邦生物上海莱士华兰生物四川远大博雅生物卫光生物双林生物山西康宝南岳生物派斯菲科博晖创新数据来源：药智网，中检院，西南证券整理11企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速CAGR2019H12020H12019年Q22020Q2天坛生物220.35236.067.13%115.58125.548.62%16%泰邦生物198.47164.37-17.18%88.7979.85-10.07%14%上海莱士105.73147.1139.14%60.1765.779.30%20%华兰生物109.71120.049.42%35.0457.4864.06%26%四川远大68.97100.4345.61%51.8457.3910.71%7%博雅生物33.2758.2575.07%15.6922.4643.09%1%卫光生物47.5953.7813.00%20.0019.12-4.39%8%双林生物39.5943.209.11%24.289.22-62.03%10%派斯菲科44.0321.35-51.53%31.4615.02-52.26%NA山西康宝42.4927.07-36.28%15.868.36-47.32%13%南岳生物41.4427.16-34.45%20.2519.56-3.42%27%博晖创新15.3923.8955.21%10.256.99-31.74%5%1.2国产人血白蛋白：2020H1批签发量同比增长6%国产人血白蛋白2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理122.静丙：新冠疫情期间静丙批签发量快速增长静丙历年批签发情况(万瓶，按年份)数据来源：药智网，中检院，西南证券整理静丙批签发量2007-2019年CAGR为+17%，近五年批签发量平稳并实现全国产。2019年，国内静丙批签发量为1184万瓶(换算成2.5g/瓶，下同)，同比增长12%；2020H1，静丙批签发量为705万瓶，同比增长50%，其中Q1批签发为456万瓶(+97%)；Q2国产批发量为249万瓶(+5%)。2020H1静丙批签发量同比快速增长，主要系2019同期基数较低。2020H1，总共13家国产企业获批静丙。其中，批签发量占比最高的分别是天坛生物166万瓶(市场份额24%)、上海莱士113万瓶(16%)、泰邦生物109万瓶(15%)和华兰生物69万瓶(10%)。上海莱士，天坛生物，卫光生物，双林生物等公司批签发量同比快速增长。2020H1静丙批签发情况(万瓶)-10%0%10%20%30%40%50%60%0200400600800100012001400静丙批签发量静丙同比增长天坛生物,166,24%上海莱士,113,16%泰邦生物,109,15%华兰生物,69,10%四川远大,50,7%博雅生物,41,6%双林生物,38,5%卫光生物,35,5%南岳生物,30,4%山西康宝,25,4%派斯菲科,23,3%绿十字,6,1%13数据来源：药智网，中检院，西南证券整理2.静丙：新冠疫情期间静丙批签发量快速增长0%10%20%30%40%50%60%70%80%90%100%天坛生物泰邦生物上海莱士华兰生物四川远大山西康宝卫光生物双林生物博雅生物南岳生物派斯菲科杰特贝林中国新兴绿十字静丙过去三年分季度批签发份额占比静丙历年批签发份额占比0%10%20%30%40%50%60%70%80%90%100%天坛生物泰邦生物上海莱士华兰生物四川远大博雅生物卫光生物山西康宝双林生物南岳生物派斯菲科杰特贝林绿十字中国新兴静丙批签发份额占比比较分散。过去十年，国内有超过十家公司获批静丙。静丙批签发量较高的企业主要是天坛生物，泰邦生物，上海莱士，华兰生物，四川远大，山西康宝等。过去三年泰邦生物，华兰生物，上海莱士，天坛生物静丙批签发占比合计超60%。2017-2019受两票制影响，行业处在去库存周期，静丙批签发量保持稳定。2020年初新冠疫情爆发，静丙作为一种提升免疫力的血制品被广泛应用于临床治疗，批签发量明显上升。14数据来源：药智网，中检院，西南证券整理2.静丙：新冠疫情期间静丙批签发量快速增长企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速CAGR2019H12020H12019年Q22020Q2天坛生物122.28164.6234.63%76.1876.590.54%38%泰邦控股92.22109.1918.41%42.8234.85-18.61%14%上海莱士23.18113.21388.32%15.1333.22119.51%15%四川远大41.2650.2421.76%21.7023.9210.23%8%华兰生物54.1369.1927.82%18.4314.35-22.15%4%卫光生物24.0434.7844.68%12.4612.611.21%16%博雅生物25.1340.7462.16%14.7313.12-10.99%17%双林生物11.4438.07232.91%3.8214.20271.51%11%山西康宝25.0424.93-0.47%12.533.17-74.73%3%派斯菲科21.0523.099.69%7.308.6117.96%2%南岳生物23.0229.9930.26%9.3010.5813.85%24%合计469.11705.1350.31%237.29249.265.04%15%%静丙2020H1/Q2批签发数量及同比增速153.免疫球蛋白：近年批签发明显回暖，2020H1批签发量显著提升免疫球蛋白批签发情况(万瓶，按年份)数据来源：中检院，西南证券整理免疫球蛋白批签发量2008-2019复合增长率(CAGR)为+2%，免疫球蛋白批签发量具有较强的周期性，大约3-5年为一个周期。近几年批签发明显回暖，2020H1批签发量显著提升。2019年，免疫球蛋白批签发为262万瓶(换算成150mg/瓶，下同)，同比增长105%；2020H1，免疫球蛋白批签发为174万瓶，同比增长258%；2020Q2，免疫球蛋白批签发为51万瓶，上年同期无批签发。2020H1，博晖创新批签发60万瓶，市场份额34%；上海莱士批签发27万瓶(-6%)，市场份额16%；德源生物批签发25万瓶，市场份额14%，博雅生物批签发21万瓶，市场份额12%。2020H1免疫球蛋白批签发情况(万瓶)博晖创新,59.73,34%上海莱士,27.04,16%德源生物,25.12,14%派斯菲科,21.98,13%博雅生物,21.40,12%卫光生物,7.80,4%-100%-50%0%50%100%150%200%250%300%350%0100200300400500600免疫球蛋白批签发量免疫球蛋白同比增长163.免疫球蛋白：近年批签发明显回暖，2020H1批签发量显著提升免疫球蛋白过去三年分季度批签发份额占比免疫球蛋白历年批签发份额占比0%20%40%60%80%100%博晖创新博雅生物丹霞生物德源生物国药兰州所国药上海所华兰生物进口-杰特贝林上海莱士0%10%20%30%40%50%60%70%80%90%100%博晖创新博雅生物德源生物华兰生物双林生物四川远大天坛生物卫光生物派斯菲科泰邦生物免疫球蛋白临床使用风险较高，每年批签发量波动较大，企业市场份额也变化明显。2017年至今，有五家公司获批较大数量免疫球蛋白。分别是博晖创新获批217万瓶，卫光生物获批118万瓶，华兰生物获批109万瓶，天坛生物获批91万瓶，上海莱士获批83万瓶。数据来源：药智网，中检院，西南证券整理173.免疫球蛋白：近年批签发明显回暖，2020H1批签发量显著提升免疫球蛋白2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-6月2020年1-6月2019年4-6月2020年4-6月免疫球蛋白（规格换算/150mg）天坛生物0.004.49上年同期无批签发0.000.00上年同期无批签发上海莱士28.6627.04-5.67%0.000.00上年同期无批签发卫光生物5.357.8045.67%0.007.80上年同期无批签发博晖创新0.0059.73上年同期无批签发0.0033.35上年同期无批签发华兰生物5.906.235.43%0.000.00上年同期无批签发博雅生物0.0021.40上年同期无批签发0.000.00上年同期无批签发德源生物0.0025.12上年同期无批签发0.009.49上年同期无批签发派斯菲科0.0021.98上年同期无批签发0.000.00上年同期无批签发泰邦控股8.600.00-100.00%0.000.00上年同期无批签发四川远大0.000.00上年同期无批签发0.000.00上年同期无批签发合计48.53173.78258.11%0.0050.63上年同期无批签发184.狂犬病免疫球蛋白：2020H1批签发回暖，卫光生物等批签发快速增长数据来源：中检院，西南证券整理狂犬病免疫球蛋白批签发量2008-2019复合年均增长率(CAGR)为+19%，2016-2019年批签发增长迅速。2019年，狂犬病免疫球蛋白批签发为1220万瓶(换算成200IU/瓶，下同)，同比增长31%；2020H1，狂犬病免疫球蛋白批签发为566万瓶，同比增长21%；2020Q2，狂犬病免疫球蛋白批签发为306万瓶，同比增长8%。2020H1共有10家公司获批狂犬病免疫球蛋白。卫光生物批签发110万瓶(+137%)，泰邦生物批签发116万瓶(+100%)，四川远大106万瓶(+15%)，这三家公司占市场份额超过60%。博雅生物，天坛生物，华兰生物等公司也有较大数量狂犬病免疫球蛋白获批。狂犬病免疫球蛋白批签发情况(万瓶，按年份)2020H1狂犬病免疫球蛋白批签发情况(万瓶)博晖创新,16,3%博雅生物,50,10%上海莱士,17,3%双林生物,47,9%四川远大,106,21%天坛生物,55,11%卫光生物,110,21%泰邦生物,116,22%-60%-40%-20%0%20%40%60%80%100%0200400600800100012001400狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长194.狂犬病免疫球蛋白：2020H1批签发回暖，卫光生物等批签发快速增长狂犬病免疫球蛋白过去三年分季度批签发份额占比狂犬病免疫球蛋白历年批签发份额占比0%10%20%30%40%50%60%70%80%90%100%博晖创新博雅生物华兰生物南岳生物上海莱士双林生物四川远大天坛生物卫光生物泰邦生物0%20%40%60%80%100%博晖创新博雅生物华兰生物进口-杰特贝林南岳生物山西康宝上海莱士双林生物四川远大天坛生物卫光生物派斯菲科泰邦生物2016年以来，国内狂犬病免疫球蛋白批签发量持续快速增长，由310万瓶快速增长到2019年的1220万瓶。主要是因为我国居民对狂犬病免疫球蛋白的认知度与必要性加深，需求端放量，带动批签发量快速增长。近三年狂犬病免疫球蛋白批签发份额较为分散，有超过十家公司获批狂犬病免疫球蛋白。其中，批签发量较大的公司是四川远大，上海莱士，泰邦生物，双林生物，华兰生物，卫光生物等。数据来源：药智网，中检院，西南证券整理204.狂犬病免疫球蛋白：2020H1批签发回暖，卫光生物等批签发快速增长狂犬病免疫球蛋白2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-6月2020年1-6月2019年4-6月2020年4-6月狂犬病免疫球蛋白（规格换算/200IU）泰邦控股57.83115.5499.79%30.8273.41138.21%四川远大92.33105.9914.79%29.6664.67118.03%上海莱士62.6516.80-73.18%0.000.00上年同期无批签发卫光生物46.41110.05137.14%37.0459.6761.09%天坛生物39.5354.6438.23%12.9427.84115.19%双林生物68.6946.99-31.59%33.1731.13-6.16%华兰生物46.0033.80-26.52%7.4516.54122.06%博雅生物25.3650.0797.46%25.3612.12-52.22%南岳生物27.4416.42-40.16%12.9916.4226.44%博晖创新0.0015.76上年同期无批签发0.004.24上年同期无批签发合计466.24566.0621.41%189.41306.0261.56%215.破伤风免疫球蛋白：2020H1华兰生物等批签发快速增长破伤风免疫球蛋白批签发情况(万瓶，按年份)数据来源：药智网，中检院，西南证券整理破伤风免疫球蛋白批签发量2008-2019年复合年均增长率(CAGR)为+12%。过去十年破伤风免疫球蛋白批发量波动较大，整体呈增长态势。2019年，破伤风免疫球蛋白批签发为640万瓶(250IU/瓶，下同)，同比增长80%，主要系华兰生物、泰邦控股、天坛生物等企业破免批签发量的快速增加所致。2020H1，破伤风免疫球蛋白批签发为293万瓶(+12%)。2020Q1，破伤风免疫球蛋白批签发162万瓶，同比上升28%；2020Q2，破伤风免疫球蛋白批签发131万瓶，同比下降3%。2020H1，泰邦生物、华兰生物与上海莱士批签发量居前三，市场份额分别达到28%，19%与16%。2020年1月至6月破伤风免疫球蛋白批签发情况(万瓶)-40%-20%0%20%40%60%80%100%120%140%0100200300400500600700破免批签发量破免同比增长博晖创新,2,1%华兰生物,56,19%上海莱士,46,16%双林生物,25,8%四川远大,35,12%天坛生物,43,15%卫光生物,5,1%泰邦生物,81,28%225.破伤风免疫球蛋白：2020H1华兰生物等批签发快速增长破伤风免疫球蛋白过去三年分季度批签发份额占比破伤风免疫球蛋白历年批签发份额占比0%10%20%30%40%50%60%70%80%90%100%华兰生物南岳生物上海莱士双林生物四川远大天坛生物卫光生物国药集团武汉所泰邦生物0%10%20%30%40%50%60%70%80%90%100%博晖创新华兰生物南岳生物上海莱士双林生物四川远大天坛生物卫光生物泰邦生物过去十年破伤风免疫球蛋白批签发份额变化不大。批签发量较高的公司是泰邦生物，四川远大，华兰生物与天坛生物等，五家公司批签发份额合计超过75%。2020H1，国内共有8个公司获批破伤风免疫球蛋白，分别是泰邦控股、华兰生物、天坛生物、四川远大、上海莱士、双林生物、卫光生物与博晖创新。数据来源：药智网，中检院，西南证券整理235.破伤风免疫球蛋白：2020H1华兰生物等批签发快速增长破伤风免疫球蛋白2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-6月2020年1-6月2019年4-6月2020年4-6月破伤风免疫球蛋白（规格换算/250IU）泰邦控股67.0681.1120.95%35.3134.29-2.89%华兰生物23.5855.77136.54%0.005.47上年同期无批签发天坛生物70.2743.17-38.57%48.4923.71-51.10%四川远大37.5134.79-7.26%18.8119.654.45%上海莱士28.5446.3962.56%13.9722.5761.61%双林生物18.5525.2936.33%8.4318.74122.37%卫光生物10.524.62-56.06%5.024.62-7.90%博晖创新5.251.98-62.33%5.251.98-62.33%南岳生物0.000.00上年同期无批签发0.000.00上年同期无批签发合计261.27293.1112.18%135.27131.03-3.14%246.乙肝免疫球蛋白：2020H1批签发回暖，四川远大等批签发快速增长乙肝免疫球蛋白批签发情况(万瓶，按年份)数据来源：中检院，西南证券整理乙肝免疫球蛋白2007-2019复合增长率(CAGR)为-1%。2019年，乙肝免疫球蛋白批签发为220万瓶(换算成100IU/瓶，下同)，同比下滑31%。2020H1，乙肝免疫球蛋白批签发为116万瓶，同比增长7%。2020Q1，同比增长205%，主要因为去年同期上海新兴召回乙肝免疫球蛋白影响，批签发基数较低。2020Q2，乙肝免疫球蛋白批签发量为76万瓶，同比下降20%。2020H1，天坛生物44万瓶(+60%)，市场份额38%；四川远大获批34万瓶(+186%)，市场份额30%；华兰生物获批22万瓶(+12%)，市场份额19%。2020H1乙肝免疫球蛋白批签发情况(万瓶)博雅生物,7,6%华兰生物,22,19%四川远大,34,30%天坛生物,44,38%泰邦生物,8,7%-40%-20%0%20%40%60%80%100%120%0100200300400500600乙肝免疫球蛋白批签发量乙肝免疫球蛋白同比增长25乙肝免疫球蛋白过去三年分季度批签发份额占比乙肝免疫球蛋白历年批签发份额占比0%10%20%30%40%50%60%70%80%90%100%博雅生物华兰生物南岳生物上海莱士四川远大天坛生物卫光生物振兴生化泰邦生物0%10%20%30%40%50%60%70%80%90%100%博晖创新博雅生物华兰生物南岳生物上海莱士四川远大天坛生物卫光生物派斯菲科泰邦生物6.乙肝免疫球蛋白：2020H1批签发回暖，四川远大等批签发快速增长近年来我国乙肝预防与治疗手段不断完善，乙肝免疫球蛋白市场需求相对有限，过去十年乙肝免疫球蛋白批签发量呈缓慢下降趋势。乙肝免疫球蛋白历年批签发份额波动较大，总体上批签发量较大的企业是华兰生物、天坛生物、上海莱士与四川远大。数据来源：药智网，中检院，西南证券整理266.乙肝免疫球蛋白：2020H1批签发回暖，四川远大等批签发快速增长乙肝免疫球蛋白2020H1/Q2批签发数量及同比增速血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-6月2020年1-6月2019年4-6月2020年4-6月乙肝免疫球蛋白（规格换算/100IU）四川远大11.8734.06186.87%11.8723.5198.01%天坛生物27.6844.0659.20%27.6844.0659.20%上海莱士39.850.00-100.00%39.850.00-100.00%华兰生物19.5621.9112.01%6.358.0025.89%泰邦控股9.128.49-6.92%9.120.00-100.00%南岳生物0.000.00上年同期无批签发0.000.00上年同期无批签发卫光生物0.000.00上年同期无批签发0.000.00上年同期无批签发博雅生物0.007.35上年同期无批签发0.000.00上年同期无批签发合计108.09115.877.20%94.8875.57-20.35%27数据来源：药智网，中检院，西南证券整理7.凝血酶原复合物：近几年批签发较为平稳，2020H1批签发提升凝血酶原复合物批签发情况(万瓶，按年份)2020H1凝血酶原复合物批签发情况(万瓶)凝血酶原复合物批签发2008-2019年CAGR为+28%。2008-2006年快速增长，2017年受两票制影响，行业整体处于去库存周期，批签发相对平稳。2020H1批签发量呈爆发性增长。2019年，凝血酶原复合物批签发为102万瓶(转换为200IU/瓶，下同)，同比增长3%；2020H1凝血酶原复合物批签量发为81万瓶(+111%)。泰邦生物批签发49万瓶(+124%)，市场份额61%，华兰生物批签发31万瓶(+113%)，市场份额39%；2020Q2，人凝血酶原复合物批签发为45万瓶，同比增长80%。泰邦生物,49,61%华兰生物,31,39%数据来源：药智网，中检院，西南证券整理-20%0%20%40%60%80%100%020406080100120凝血酶原复合物批签发量凝血酶原复合物同比增长287.凝血酶原复合物：近几年批签发较为平稳，2020H1批签发提升凝血酶原复合物历年批签发份额占比2008-2014年间，华兰生物的凝血酶原复合物批签发份额占70%以上。2015年以后，国内凝血酶原复合物批签发企业以泰邦生物与华兰生物为主。上海新兴事件过后，国内凝血酶原复合物生产企业只有泰邦生物与华兰生物两家。凝血酶原复合物过去三年分季度批签发份额占比0%10%20%30%40%50%60%70%80%90%100%华兰生物上海莱士泰邦生物天坛生物中国新兴0%10%20%30%40%50%60%70%80%90%100%华兰生物上海莱士泰邦生物中国新兴数据来源：药智网，中检院，西南证券整理298.凝血因子Ⅷ：近几年批签发稳步增长，上海莱士提升明显凝血因子Ⅷ批签发情况(万瓶，按年份)凝血因子VIII行业2008-2019年CAGR为-2%，近几年批签发量稳步增长。2019年，凝血因子Ⅷ批签发为181万瓶(转换为200IU/瓶，下同)，同比增长8%。2020H1，凝血因子Ⅷ批签发为101万瓶(+32%)，同比快速增长。2020Q2，凝血因子Ⅷ批签发为41万瓶(+20%)。2020H1共有四家公司获批凝血因子VIII，分别是华兰生物，泰邦控股，上海莱士和绿十字。上海莱士批签发33万瓶(+387%)，市场份额33%；华兰生物批签发30万瓶(-3%)，市场份额29%；泰邦生物批签发25万瓶(+0.2%)，市场份额25%；绿十字批签发13万瓶(+54%)，市场份额13%。2020H1凝血因子VIII批签发情况(万瓶)-100%-80%-60%-40%-20%0%20%40%60%80%050100150200250300350凝血因子VIII批签发量凝血因子VIII同比增长上海莱士,33,33%华兰生物,30,29%泰邦生物,25,25%绿十字,13,13%数据来源：药智网，中检院，西南证券整理308.凝血因子Ⅷ：近几年批签发稳步增长，上海莱士提升明显凝血因子Ⅷ历年批签发份额占比凝血因子Ⅷ过去三年分季度批签发份额占比0%10%20%30%40%50%60%70%80%90%100%中国新兴天坛生物泰邦生物上海莱士绿十字华兰生物国药上海所0%10%20%30%40%50%60%70%80%90%100%中国新兴天坛生物泰邦生物上海莱士绿十字华兰生物过去十年，凝血因子Ⅷ批签发量最高的是华兰生物，绿十字(中国)与上海莱士。近几年泰邦生物进入凝血因子Ⅷ市场，批签发占比逐渐分散。2019Q1-2020Q2，凝血因子Ⅷ批签发份额最高的公司是上海莱士，泰邦生物与华兰生物，三家公司合计市场份额超过80%，批签发量相对集中。数据来源：药智网，中检院，西南证券整理318.凝血因子Ⅷ：近几年批签发稳步增长，上海莱士提升明显企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速CAGR2019H12020H12019年Q22020Q2华兰生物30.6429.58-3.43%6.5910.2355.21%17.29%泰邦控股24.5724.630.23%17.1514.45-15.79%27.31%上海莱士6.7732.96386.81%3.8014.45280.24%16.12%绿十字8.6813.3653.97%6.301.62-74.28%11.90%合计70.65100.5342.29%33.8540.7520.38%18.24%凝血因子VIII2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理329.纤维蛋白原：近几年批签发略有下滑，2020年二季度同比快速增长纤维蛋白原批签发情况(万瓶，按年份)纤维蛋白原2008-2019年CAGR为+49%，近几年批签发量略有下滑。2019年纤维蛋白原批签发为89万瓶(0.5g/瓶，下同)，与2018年基本持平；2020H1，纤维蛋白原批签发为62万瓶，同比上升38%；2020Q2，纤维蛋白原批签发为35万瓶，同比上升126%。2020H1纤维蛋白原共有五家公司获批。分公司来看，上海莱士获批26万瓶(+1066%)，占市场份额42%；泰邦生物批签18万瓶(+6%)，占市场份额29%；博雅生物获批11万瓶(-46%)，占市场份额17%。2020H1纤维蛋白原批签发情况(万瓶)博雅生物,11,17%绿十字,3,5%上海莱士,26,42%派斯菲科,4,7%泰邦生物,18,29%数据来源：药智网，中检院，西南证券整理-50%0%50%100%150%200%250%300%350%400%020406080100120纤维蛋白原批签发量纤维蛋白原同比增长339.纤维蛋白原：近几年批签发略有下滑，2020年二季度同比快速增长纤维蛋白原过去三年分季度批签发份额占比纤维蛋白原历年批签发份额占比过去十年，纤维蛋白原批签发量最高的是上海莱士，博雅生物。近几年泰邦生物、华兰生物等公司进入纤维蛋白原市场，市场占比逐渐分散。近三年纤维蛋白原市场份额最高的公司是上海莱士，泰邦生物与博雅生物，三家公司合计市场份额超过70%，批签发量相对集中。0%10%20%30%40%50%60%70%80%90%100%博雅生物华兰生物绿十字上海莱士天坛生物卫光生物中国新兴派斯菲科泰邦生物0%10%20%30%40%50%60%70%80%90%100%博雅生物国药上海所华兰生物绿十字上海莱士泰邦生物数据来源：药智网，中检院，西南证券整理349.纤维蛋白原：近几年批签发略有下滑，2020年二季度同比快速增长纤维蛋白原2020H1/Q2批签发数量及同比增速数据来源：药智网，中检院，西南证券整理血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019年1-6月2020年1-6月2019年4-6月2020年4-6月纤维蛋白原(规格换算/0.5g)泰邦控股16.9317.945.96%5.4111.61114.65%博雅生物19.6210.68-45.55%7.527.23-3.82%上海莱士2.2526.231065.65%0.0011.00-绿十字2.783.3721.32%1.782.3230.25%派斯菲科0.734.22481.77%0.732.75278.57%卫光生物0.000.00-0.000.00-中国新兴2.840.00-100.00%0.000.00-华兰生物0.240.00-100.00%0.000.00-合计45.3962.4437.59%15.4334.91126.19%35分公司来看：华兰生物：2020H1获批8种血制品。人血白蛋白获批120万瓶(+9%)，破免、PCC同比增长超100%。整体批签发量较去年同期稳步增长。双林生物：2020H1获批4种血制品。人血白蛋白获批43万瓶(+9%)，静丙获批38万瓶(+233%)，破免增长36%。卫光生物：2020H1获批4种血制品。人血白蛋白获批54万瓶(+13%)，静丙获批35万瓶(+45%)，狂免获批110万瓶(+137%)。天坛生物：2020H1获批5种血制品。人血白蛋白获批236万瓶(+7%)；乙肝免疫球蛋白、狂免、静丙同比增长超30%，免疫球蛋白整体快速增长。博雅生物：2020H1获批6种血制品。人血白蛋白获批58万瓶(+75%)，静丙获批41万瓶(+62%)，狂免同比增长超50%。公司新增免疫球蛋白与乙肝免疫球蛋白两种血制品批签发。上海莱士：2020H1获批9种血制品，批签发量较去年同期快速增长。人血白蛋白获批147万瓶，(+39%)，静丙获批113万瓶(+388%)，凝血因子类同比增长超300%，其中纤原同比增长高达1066%。博晖创新：2020H1冻干静丙同比增长688%，人血白蛋白增长55%。泰邦生物：2020H1PCC、狂免同比增长超100%。2020H1血制品公司批签发情况3637华兰生物2020H1血制品共有八种血制品获批，批签发量整体较去年同期稳步增长。人血白蛋白获批120万瓶，同比增长9%，静丙获批69万瓶(+28%)。破伤风免疫球蛋白获批56万瓶(+137%)，凝血酶原复合物获批31万瓶(+113%)，同比快速增长。乙肝免疫球蛋白获批22万瓶(+12%)，免疫球蛋白获批6万瓶(+5%),同比稳定增长。狂犬病免疫球蛋白获批34万瓶(-27%)，凝血因子VIII获批30万瓶(-3%)，同比小幅下降。血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)华兰生物109.71120.049.42%35.0457.4864.06%静注人免疫球蛋白(规格换算/2.5g)54.1369.1927.82%18.4314.35-22.15%狂犬病免疫球蛋白(规格换算/200IU)46.0033.80-26.52%7.4516.54122.06%免疫球蛋白(规格换算/150mg)5.906.235.43%0.000.00上年同期无批签发人凝血酶原复合物(规格换算/200IU)14.7331.44113.39%14.7313.15-10.75%30.6429.58-3.43%6.5910.2355.21%凝血因子VIII(规格换算/200IU)破伤风免疫球蛋白(规格换算/250IU)23.5855.77136.54%0.005.47上年同期无批签发乙肝免疫球蛋白(规格换算/100IU)19.5621.9112.01%6.358.0025.89%华兰生物(002007)：破免、PCC同比增长超100%数据来源：药智网，中检院，西南证券整理华兰生物2020H1/Q2批签发数量及同比增长38华兰生物凝血酶原复合物批签发情况(万瓶，按年份)华兰生物凝血因子VIII批签发情况(万瓶，按年份)华兰生物(002007)：破免、PCC同比增长超100%数据来源：药智网，中检院，西南证券整理-120%-100%-80%-60%-40%-20%0%20%40%60%80%100%0204060801001201401601802002008200920102011201220132014201520162017201820192020H1凝血因子VIII批签发量凝血因子VIII同比增长华兰生物人血白蛋白批签发情况(万瓶换算成10g，按年份)-100%0%100%200%300%400%500%05010015020025030020072008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长华兰生物静丙批签发情况(万瓶换算成2.5g，按年份)-40%-20%0%20%40%60%80%100%120%02040608010012014016018020072008200920102011201220132014201520162017201820192020H1静丙批签发量静丙同比增长-40%-20%0%20%40%60%80%100%120%140%160%0102030405060702008200920102011201220132014201520162017201820192020H1凝血酶原复合物批签发量凝血酶原复合物同比增长39华兰生物破伤风免疫球蛋白批签发情况(万瓶，按年份)华兰生物乙肝免疫球蛋白批签发情况(万瓶，按年份)华兰生物(002007)：破免、PCC同比增长超100%数据来源：药智网，中检院，西南证券整理华兰生物狂犬病免疫球蛋白批签发情况(万瓶，按年份)华兰生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)-100%-50%0%50%100%150%200%250%0204060801001201401602008200920102011201220132014201520162017201820192020H1破伤风免疫球蛋白批签发量破伤风免疫球蛋白同比增长-100%-50%0%50%100%150%200%0204060801001201402008200920102011201220132014201520162017201820192020H1乙肝免疫球蛋白批签发量乙肝免疫球蛋白同比增长-150%-100%-50%0%50%100%150%200%250%0204060801001201401602008200920102011201220132014201520162017201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长-150%-100%-50%0%50%100%150%01020304050602008200920102011201220132014201520162017201820192020H1免疫球蛋白批签发量免疫球蛋白同比增长40双林生物2020H1有四种血制品获批。人血白蛋白获批43万瓶，同比增长9%，静丙获批38万瓶(+233%)。破伤风免疫球蛋白获批25万瓶(+36%)，同比快速增长。狂犬病免疫球蛋白获批47万瓶(-32%)，同比大幅下降。血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)双林生物39.5943.209.11%24.289.22-62.03%静注人免疫球蛋白(规格换算/2.5g)11.4438.07232.91%3.8214.20271.51%狂犬病免疫球蛋白(规格换算/200IU)68.6946.99-31.59%33.1731.13-6.16%破伤风免疫球蛋白(规格换算/250IU)18.5525.2936.33%8.4318.74122.37%双林生物(000403)：静丙同比增长达233%，破免增长36%数据来源：药智网，中检院，西南证券整理双林生物2020H1/Q2批签发数量及同比增长41双林生物人血白蛋白批签发情况(万瓶换算成10g，按年份)双林生物静丙批签发情况(万瓶换算成2.5g，按年份)双林生物狂犬病免疫球蛋白批签发情况(万瓶，按年份)双林生物破伤风免疫球蛋白批签发情况(万瓶，按年份)双林生物(000403)：静丙同比增长达233%，破免增长36%数据来源：药智网，中检院，西南证券整理-20%-10%0%10%20%30%40%50%60%02040608010012020072008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-40%-20%0%20%40%60%80%100%010203040506020072008200920102011201220132014201520162017201820192020H1静丙批签发量静丙同比增长-100%-50%0%50%100%150%200%250%300%350%400%450%0204060801001201401601802002008200920102011201220132014201520162017201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长-200%-100%0%100%200%300%400%500%600%700%0102030405060702011201220132014201520162017201820192020H1破伤风免疫球蛋白批签发量破伤风免疫球蛋白同比增长42血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)卫光生物47.5953.7813.00%20.0019.12-4.39%静注免疫球蛋白(规格换算/2.5g)24.0434.7844.68%12.4612.611.21%狂犬病免疫球蛋白(规格换算/200IU)46.41110.05137.14%37.0459.6761.09%破伤风免疫球蛋白(规格换算/250IU)10.524.62-56.06%5.024.62-7.90%卫光生物2020H1有四种血制品获批。人血白蛋白获批54万瓶，同比增长+13%，静丙获批35万瓶(+45%)。狂犬病免疫球蛋白获批110万瓶(+137%)，同比快速增长。破伤风免疫球蛋白获批5万瓶(-56%)，同比大幅下降。卫光生物(002880)：狂免同比增长137%，静丙增长45%数据来源：药智网，中检院，西南证券整理卫光生物2020H1/Q2批签发数量及同比增长43卫光生物人血白蛋白批签发情况(万瓶换算成10g，按年份)卫光生物狂犬病免疫球蛋白批签发情况(万瓶换算成200IU，按年份)卫光生物静丙批签发情况(万瓶换算成2.5g，按年份)卫光生物破伤风免疫球蛋白批签发情况(万瓶，按年份)数据来源：药智网，中检院，西南证券整理-30%-20%-10%0%10%20%30%40%50%60%02040608010012020072008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-40%-20%0%20%40%60%80%100%120%140%010203040506020072008200920102011201220132014201520162017201820192020H1静丙批签发量静丙同比增长卫光生物(002880)：狂免同比增长137%，静丙增长45%-100%0%100%200%300%400%500%020406080100120201220132014201520162017201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长-200%0%200%400%600%800%1000%051015202530352011201220132014201520162017201820192020H1破伤风免疫球蛋白批签发量破伤风免疫球蛋白同比增长44天坛生物人血白蛋白批签发情况(万瓶换算成10g，按年份)天坛生物静丙批签发情况(万瓶换算成2.5g，按年份)天坛生物2020H1有五种血制品获批。人血白蛋白获批236万瓶，同比增长7%，静丙获批165万瓶(+35%)。狂犬病免疫球蛋白获批55万瓶(+38%)、乙肝免疫球蛋白获批44万瓶(+44%)，同比快速增长。破伤风免疫球蛋白获批43万瓶(-39%)，同比大幅下降。血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)天坛生物220.35236.067.13%115.58125.548.62%静注人免疫球蛋白(规格换算/2.5g)122.28164.6234.63%76.1876.590.54%破伤风免疫球蛋白(规格换算/250IU)70.2743.17-38.57%48.4923.71-51.10%狂犬病免疫球蛋白(规格换算/200IU)39.5354.6438.23%12.9427.84115.19%乙肝免疫球蛋白(规格换算/100IU)27.6844.0659.20%27.6844.0659.20%天坛生物(600161)：乙免、狂免、静丙同比增长超30%数据来源：药智网，中检院，西南证券整理天坛生物2020H1/Q2批签发数量及同比增长-40%-20%0%20%40%60%80%100%120%0501001502002503003504004505002008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-20%0%20%40%60%80%100%120%0501001502002503003502008200920102011201220132014201520162017201820192020H1静丙批签发量静丙同比增长45天坛生物狂犬病免疫球蛋白批签发情况(万瓶，按年份)天坛生物破伤风免疫球蛋白批签发情况(万瓶，按年份)天坛生物乙肝免疫球蛋白批签发情况(万瓶，按年份)天坛生物(600161)：乙免、狂免、静丙同比增长超30%数据来源：药智网，中检院，西南证券整理0%10%20%30%40%50%60%70%80%020406080100120201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长-100%-50%0%50%100%150%200%0204060801001201401602008200920102011201220132014201520162017201820192020H1破伤风免疫球蛋白批签发量破伤风免疫球蛋白同比增长-80%-60%-40%-20%0%20%40%60%80%01020304050607080901002008200920102011201220132014201520162017201820192020H1乙肝免疫球蛋白批签发量乙肝免疫球蛋白同比增长46上海莱士2020H1有九种血制品获批，整体批签发量相较去年同期快速增长。人血白蛋白获批147万瓶，同比增长39%，静丙获批113万瓶(+388%)。纤维蛋白原获批26万瓶(+1066%)，凝血因子VIII获批33万瓶(+387%)，破伤风免疫球蛋白获批46万瓶(+63%)，同比大幅增长。狂犬病免疫球蛋白获批17万瓶(-73%)，冻干静丙获批21万瓶(+40%)、免疫球蛋白获批27万瓶(-6%)，同比呈下降趋势。血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)上海莱士105.73147.1139.14%60.1765.779.30%静注人免疫球蛋白(规格换算/2.5g)23.18113.21388.32%15.1333.22119.51%冻干静注人免疫球蛋白(规格换算/2.5g)15.1621.2340.06%8.634.37-49.32%狂犬病免疫球蛋白(规格换算/200IU)62.6516.80-73.18%0.000.00上年同期无批签发免疫球蛋白(规格换算/150mg)28.6627.04-5.67%0.000.00上年同期无批签发凝血因子VIII(规格换算/200IU)6.7732.96386.81%3.8014.45280.24%破伤风免疫球蛋白(规格换算/250IU)28.5446.3962.56%13.9722.5761.61%纤维蛋白原(规格换算/0.5g)2.2526.231065.65%0.0011.00上年同期无批签发乙肝免疫球蛋白(规格换算/100IU)39.850.00-100.00%39.850.00-100.00%上海莱士(002252)：纤原同比增长高达1066%，静丙、八因子增长超300%数据来源：药智网，中检院，西南证券整理上海莱士2020H1/Q2批签发数量及同比增长47上海莱士纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)上海莱士凝血因子VIII批签发情况(万瓶，按年份)上海莱士人血白蛋白批签发情况(万瓶换算成10g，按年份)上海莱士静丙批签发情况(万瓶换算成2.5g，按年份)上海莱士(002252)：纤原同比增长高达1066%，静丙、八因子增长超300%数据来源：药智网，中检院，西南证券整理-50%0%50%100%150%200%05010015020025030020072008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-40%-20%0%20%40%60%80%100%020406080100120140160静丙批签发量静丙同比增长-100%-50%0%50%100%150%0204060801001202008200920102011201220132014201520162017201820192020H1凝血因子VIII批签发量凝血因子VIII同比增长-100%-50%0%50%100%150%200%250%01020304050602008200920102011201220132014201520162017201820192020H1纤维蛋白原批签发量纤维蛋白原同比增长48上海莱士破伤风免疫球蛋白批签发情况(万瓶，按年份)上海莱士乙肝免疫球蛋白批签发情况(万瓶，按年份)上海莱士狂犬病免疫球蛋白批签发情况(万瓶，按年份)上海莱士免疫球蛋白批签发情况(万瓶换算150mg，按年份)上海莱士(002252)：纤原同比增长高达1066%，静丙、八因子增长超300%数据来源：药智网，中检院，西南证券整理-60%-40%-20%0%20%40%60%80%01020304050607020132014201520162017201820192020H1破伤风免疫球蛋白签批放量破伤风免疫球蛋白同比增长-100%0%100%200%300%400%01020304050607080200920102011201220132014201520162017201820192020H1乙肝免疫球蛋白批签发量乙肝免疫球蛋白同比增长-150%-100%-50%0%50%100%150%200%050100150200250201220132014201520162017201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长-120%-100%-80%-60%-40%-20%0%05101520253035201220132014201520162017201820192020H1免疫球蛋白批签发量免疫球蛋白同比增长49博雅生物2020H1有六种血制品获批，新增免疫球蛋白与乙肝免疫球蛋白两种血制品批签发，冻干静丙无批签发，整体批签发量相较去年同期快速增长。人血白蛋白获批58万瓶，同比增长75%，静丙获批41万瓶(+62%)。狂犬病免疫球蛋白获批50万瓶(+97%)，同比大幅增长。纤维蛋白原获批11万瓶(-46%)，同比大幅下降。血制品名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)33.2758.2575.07%15.6922.4643.09%静注人免疫球蛋白(规格换算/10g)25.1340.7462.16%14.7313.12-10.99%狂犬病免疫球蛋白(规格换算/200IU)25.3650.0797.46%25.3612.12-52.22%免疫球蛋白(规格换算/150mg)0.0021.40上年同期无批签发0.000.00上年同期无批签发纤维蛋白原(规格换算/0.5g)19.6210.68-45.55%7.527.23-3.82%乙肝免疫球蛋白(规格换算/100IU)0.007.35上年同期无批签发0.000.00上年同期无批签发博雅生物(300294)：狂免、静丙同比增长超50%数据来源：药智网，中检院，西南证券整理博雅生物2020H1/Q2批签发数量及同比增长50博雅生物纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)博雅生物乙型肝炎免疫蛋白批签发情况(万瓶，按年份)博雅生物(300294)：狂免、静丙同比增长超50%数据来源：药智网，中检院，西南证券整理博雅生物人血白蛋白批签发情况(万瓶，换算成10g，按年份)博雅生物静丙批签发情况(万瓶换算成2.5g，按年份)-100%0%100%200%300%400%500%600%0102030405060708020072008200920102011201220132014201520162017201820192020H1静丙批签发量静丙同比增长-100%0%100%200%300%400%500%02040608010020072008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-100%-50%0%50%100%150%200%250%300%350%010203040506020102011201220132014201520162017201820192020H1纤维蛋白原批签发量纤维蛋白原同比增长-120%-100%-80%-60%-40%-20%0%024681012141618201220132014201520162017201820192020H1乙肝免疫球蛋白批签发量乙肝免疫球蛋白同比增长51博雅生物狂犬病免疫球蛋白批签发情况(万瓶，换算成200IU，按年份)博雅生物(300294)：狂免、静丙同比增长超50%数据来源：药智网，中检院，西南证券整理博雅生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)0%20%40%60%80%100%120%051015202520192020H1免疫球蛋白批签发量免疫球蛋白同比增长-100%0%100%200%300%400%500%600%700%01020304050607020132014201520162017201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长52博晖创新人血白蛋白批签发情况(万瓶换算成10g，按年份)博晖创新冻干静丙批签发情况(万瓶换算成2.5g，按年份)博晖创新2020H1有五种血制品获批，整体批签发量快速增长。人血白蛋白获批24万瓶，同比增长55%，冻干静丙获批33万瓶(+688%)。狂犬病免疫球蛋白、免疫球蛋白去年同期无批签发，H1批签发量分别为16万瓶和60万瓶。破伤风免疫球蛋白批签发量2万瓶(-62%)，同比大幅下降。血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)博晖创新15.3923.8955.21%10.256.99-31.74%冻干静注人免疫球蛋白(规格换算/2.5g)4.2433.38688.14%2.3211.23385.03%狂犬病免疫球蛋白(规格换算/200IU)0.0015.76上年同期无批签发0.004.24上年同期无批签发免疫球蛋白(规格换算/150mg)0.0059.73上年同期无批签发0.0033.35上年同期无批签发破伤风免疫球蛋白(规格换算/250IU)5.251.98-62.33%5.251.98-62.33%博晖创新(300318)：冻干静丙同比增长688%，人白增长55%数据来源：药智网，中检院，西南证券整理博晖创新2020H1/Q2批签发数量及同比增长-200%0%200%400%600%800%1000%01020304050607020072008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-200%-100%0%100%200%300%400%05101520253035404520072008200920102011201220132014201520162017201820192020H1冻干静丙批签发量冻干静丙同比增长53博晖创新狂犬病免疫球蛋白批签发情况(万瓶，按年份)博晖创新破伤风免疫球蛋白批签发情况(万瓶，按年份)博晖创新免疫球蛋白批签发情况(万瓶换算成150mg，按年份)博晖创新(300318)：冻干静丙同比增长688%，人白增长55%数据来源：药智网，中检院，西南证券整理-1000%0%1000%2000%3000%4000%5000%6000%7000%0204060801001201401602008200920102011201220132014201520162017201820192020H1免疫球蛋白批签发量免疫球蛋白同比增长-1%-1%-1%0%0%0%051015202530201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长0%20%40%60%80%100%120%012345620192020H1破伤风免疫球蛋白批签发量破伤风免疫球蛋白同比增长54泰邦生物2020H1有八种血制品获批，其中免疫蛋白H1无批签发，批签发量较去年同期整体保持稳定。人血白蛋白获批164万瓶，同比下降17%，静丙获批109万瓶(+18%)。凝血酶原复合物获批49万瓶(+124%)，狂犬病免疫球蛋白获批115万瓶(+100%)，同比快速增长。破伤风免疫球蛋白获批81万瓶(+21%)，纤维蛋白原获批18万瓶(+6%)，凝血因子VIII获批25万瓶(+0%)，同比稳定增长。乙肝免疫球蛋白获批8万瓶(-7%)，同比小幅下降。血制品名称企业名称规格换算后批签发数量(万支)同比增速规格换算后批签发数量(万支)同比增速2019H12020H12019年Q22020Q2人血白蛋白(规格换算/10g)泰邦生物198.47164.37-17.18%88.7979.85-10.07%静注人免疫球蛋白(规格换算/10g)92.22109.1918.41%42.8234.85-18.61%狂犬病免疫球蛋白(规格换算/200IU)57.83115.5499.79%30.8273.41138.21%人凝血酶原复合物(规格换算/200IU)22.0849.46124.03%10.2331.74210.40%凝血因子VIII(规格换算/200IU)24.5724.630.23%17.1514.45-15.79%破伤风免疫球蛋白(规格换算/250IU)67.0681.1120.95%35.3134.29-2.89%纤维蛋白原(规格换算/0.5g)16.9317.945.96%5.4111.61114.65%乙肝免疫球蛋白(规格换算/100IU)9.128.49-6.92%9.120.00-100.00%泰邦生物(CBPO.O)：PCC、狂免增长超100%数据来源：药智网，中检院，西南证券整理泰邦生物2020H1/Q2批签发数量及同比增长55泰邦生物凝血因子VIII批签发情况(万瓶，按年份)泰邦生物狂犬病免疫球蛋白批签发情况(万瓶，按年份)泰邦生物静丙批签发情况(万瓶换算成2.5g，按年份)泰邦生物人血白蛋白批签发情况(万瓶换算成10g，按年份)泰邦生物(CBPO.O)：PCC、狂免增长超100%数据来源：药智网，中检院，西南证券整理-20%0%20%40%60%80%100%0501001502002503003504004502008200920102011201220132014201520162017201820192020H1人血蛋白批签发量人血蛋白同比增长-60%-40%-20%0%20%40%60%80%100%120%05010015020025020072008200920102011201220132014201520162017201820192020H1静丙批签发量静丙同比增长-40%-20%0%20%40%60%80%100%120%010203040506020132014201520162017201820192020H1凝血因子VIII批签发量凝血因子VIII同比增长-200%-100%0%100%200%300%400%500%600%0204060801001201401601802002008200920102011201220132014201520162017201820192020H1狂犬病免疫球蛋白批签发量狂犬病免疫球蛋白同比增长56泰邦生物破伤风免疫球蛋白批签发情况(万瓶，按年份)泰邦生物乙肝免疫球蛋白批签发情况(万瓶，按年份)泰邦生物纤维蛋白原批签发情况(万瓶换算成0.5g，按年份)泰邦生物凝血酶原复合物批签发情况(万瓶，按年份)泰邦生物(CBPO.O)：PCC、狂免增长超100%数据来源：药智网，中检院，西南证券整理-100%-50%0%50%100%150%200%010203040506070201520162017201820192020H1凝血酶原复合物批签发量凝血酶原复合物同比增长0%20%40%60%80%100%120%140%160%180%200%05101520253035201820192020H1纤维蛋白原批签发量纤维蛋白原同比增长-100%-50%0%50%100%150%200%250%300%350%0204060801001201401601802008200920102011201220132014201520162017201820192020H1破伤风免疫球蛋白签批放量破伤风免疫球蛋白同比增长-100%-50%0%50%100%150%200%010203040502008200920102011201220132014201520162017201820192020H1乙肝免疫球蛋白批签发量乙肝免疫球蛋白同比增长57泰邦生物免疫球蛋白批签发情况(万瓶换算150mg，按年份)泰邦生物(CBPO.O)：PCC、狂免增长超100%数据来源：药智网，中检院，西南证券整理-120%-100%-80%-60%-40%-20%0%20%40%0204060801001201402008200920102011201220132014201520162017201820192020H1免疫球蛋白批签发量免疫球蛋白同比增长西南证券研究发展中心西南证券投资评级说明公司评级买入：未来6个月内，个股相对沪深300指数涨幅在20%以上持有：未来6个月内，个股相对沪深300指数涨幅介于10%与20%之间中性：未来6个月内，个股相对沪深300指数涨幅介于-10%与10%之间回避：未来6个月内，个股相对沪深300指数涨幅介于-20%与-10%之间卖出：未来6个月内，个股相对沪深300指数涨幅在-20%以下行业评级强于大市：未来6个月内，行业整体回报高于沪深300指数5%以上跟随大市：未来6个月内，行业整体回报介于沪深300指数-5%与5%之间弱于大市：未来6个月内，行业整体回报低于沪深300指数-5%以下分析师承诺报告署名分析师具有中国证券业协会授予的证券投资咨询执业资格并注册为证券分析师，报告所采用的数据均来自合法合规渠道，分析逻辑基于分析师的职业理解，通过合理判断得出结论，独立、客观地出具本报告。分析师承诺不曾因，不因，也将不会因本报告中的具体推荐意见或观点而直接或间接获取任何形式的补偿。重要声明西南证券股份有限公司(以下简称“本公司”)具有中国证券监督管理委员会核准的证券投资咨询业务资格。本公司与作者在自身所知情范围内，与本报告中所评价或推荐的证券不存在法律法规要求披露或采取限制、静默措施的利益冲突。《证券期货投资者适当性管理办法》于2017年7月1日起正式实施，本报告仅供本公司客户中的专业投资者使用，若您并非本公司客户中的专业投资者，为控制投资风险，请取消接收、订阅或使用本报告中的任何信息。本公司也不会因接收人收到、阅读或关注自媒体推送本报告中的内容而视其为客户。本公司或关联机构可能会持有报告中提到的公司所发行的证券并进行交易，还可能为这些公司提供或争取提供投资银行或财务顾问服务。。本报告中的信息均来源于公开资料，本公司对这些信息的准确性、完整性或可靠性不作任何保证。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断，本报告所指的证券或投资标的的价格、价值及投资收入可升可跌，过往表现不应作为日后的表现依据。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告，本公司不保证本报告所含信息保持在最新状态。同时，本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。本报告仅供参考之用，不构成出售或购买证券或其他投资标的要约或邀请。在任何情况下，本报告中的信息和意见均不构成对任何个人的投资建议。投资者应结合自己的投资目标和财务状况自行判断是否采用本报告所载内容和信息并自行承担风险，本公司及雇员对投资者使用本报告及其内容而造成的一切后果不承担任何法律责任。本报告版权为西南证券所有，未经书面许可，任何机构和个人不得以任何形式翻版、复制和发布。如引用须注明出处为“西南证券”，且不得对本报告进行有悖原意的引用、删节和修改。未经授权刊载或者转发本报告的，本公司将保留向其追究法律责任的权利。西南证券研究发展中心上海重庆地址：上海市浦东新区陆家嘴东路166号中国保险大厦20楼地址：重庆市江北区桥北苑8号西南证券大厦3楼邮编：200120邮编：400023北京深圳地址：北京市西城区南礼士路66号建威大厦1501-1502地址：深圳市福田区深南大道6023号创建大厦4楼邮编：100045邮编：518040西南证券机构销售团队区域姓名职务座机手机邮箱上海蒋诗烽地区销售总监021-6841530918621310081jsf@swsc.com.cn张方毅高级销售经理021-6841395915821376156zfyi@swsc.com.cn杨博睿销售经理021-6841586113166156063ybz@swsc.com.cn吴菲阳销售经理021-6841502016621045018wfy@swsc.com.cn付禹销售经理021-6841552313761585788fuyu@swsc.com.cn北京张岚高级销售经理1860124180318601241803zhanglan@swsc.com.cn高妍琳销售经理1581080951115810809511gyl@swsc.com.cn广深王湘杰地区销售副总监0755-2667151713480920685wxj@swsc.com.cn陈慧玲高级销售经理1850070933018500709330chl@swsc.com.cn谭凌岚销售经理1364236260113642362601tll@swsc.com.cn陈霄（广州）销售经理1552101096815521010968chenxiao@swsc.com.cn西南证券研究发展中心","data":[{"id":"1","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"人血白蛋白：2020H1人白批签发量超3000万瓶","content_offset":["121","146"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3000万瓶","140","146"],"indicator_element":{"时间":["2020H1","127","133"],"产品":["人白","133","135"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长35%","content_offset":["147","154"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["35%","151","154"],"indicator_element":{"时间":["2020H1","127","133"],"产品":["人白","133","135"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中Q1增长83%","content_offset":["155","164"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["83%","161","164"],"indicator_element":{"时间":["Q1","157","159"],"产品":["人白","133","135"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1进口2029万瓶(+58%)","content_offset":["187","207"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2029万瓶","195","201"],"indicator_element":{"时间":["2020H1","187","193"],"产品":["人白","133","135"],"渠道":["进口","193","195"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1进口2029万瓶(+58%)","content_offset":["187","207"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+58%","202","206"],"indicator_element":{"时间":["2020H1","187","193"],"产品":["人白","133","135"],"渠道":["进口","193","195"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"占整体66%","content_offset":["208","214"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["66%","211","214"],"indicator_element":{"时间":["2020H1","127","133"],"产品":["人白","133","135"],"渠道":["进口","193","195"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"国产1051万瓶(+6%)","content_offset":["215","228"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1051万瓶","217","223"],"indicator_element":{"时间":["2020H1","127","133"],"产品":["人白","133","135"],"渠道":["国产","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"国产1051万瓶(+6%)","content_offset":["215","228"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+6%","224","227"],"indicator_element":{"时间":["2020H1","127","133"],"产品":["人白","133","135"],"渠道":["国产","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"占整体34%","content_offset":["229","235"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["34%","232","235"],"indicator_element":{"时间":["2020H1","187","193"],"产品":["人白","133","135"],"渠道":["国产","215","217"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"免疫球蛋白：2020H1静丙批签发量为705万瓶","content_offset":["236","260"],"indicators":[{"indicator_name":"批签发量","indicator_value":["705万瓶","255","260"],"indicator_element":{"时间":["2020H1","242","248"],"产品":["静丙","248","250"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长50%","content_offset":["261","268"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["50%","265","268"],"indicator_element":{"时间":["2020H1","187","193"],"产品":["静丙","248","250"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其他品种如狂免566万瓶(+21%)、破免293万瓶(+12%)；免疫球蛋白174万瓶(+258%)、乙免116万瓶(+7%)","content_offset":["269","332"],"indicators":[{"indicator_name":"批签发量","indicator_value":["566万瓶","276","281"],"indicator_element":{"产品":["狂免","274","276"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["293万瓶","290","295"],"indicator_element":{"产品":["破免","288","290"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["174万瓶","307","312"],"indicator_element":{"产品":["免疫球蛋白","302","307"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["116万瓶","322","327"],"indicator_element":{"产品":["乙免","320","322"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其他品种如狂免566万瓶(+21%)、破免293万瓶(+12%)；免疫球蛋白174万瓶(+258%)、乙免116万瓶(+7%)","content_offset":["269","332"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+21%","282","286"],"indicator_element":{"产品":["狂免","274","276"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+12%","296","300"],"indicator_element":{"产品":["破免","288","290"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+258%","313","318"],"indicator_element":{"产品":["免疫球蛋白","302","307"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量同比","indicator_value":["+7%","328","331"],"indicator_element":{"产品":["乙免","320","322"],"时间":["2020H1","187","193"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"凝血因子类：PCC81万瓶(+111%)、凝血因子VIII101万瓶(+43%)。纤原62万瓶(+38%)","content_offset":["333","386"],"indicators":[{"indicator_name":"批签发量","indicator_value":["81万瓶","342","346"],"indicator_element":{"产品":["PCC","339","342"],"时间":["2020H1","242","248"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["101万瓶","362","367"],"indicator_element":{"产品":["凝血因子VIII","354","362"],"时间":["2020H1","242","248"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["62万瓶","376","380"],"indicator_element":{"产品":["纤原","374","376"],"时间":["2020H1","242","248"]},"indicator_supplement":{"属性":""}},{"indicator_name":"批签发量","indicator_value":["","333","333"],"indicator_element":{"时间":["2020H1","242","248"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2007-2019年人血白蛋白批签发复合年均增长率(CAGR)为+22%","content_offset":["3045","3081"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+22%","3077","3081"],"indicator_element":{"时间":["2007-2019年","3045","3055"],"产品":["人血白蛋白","3055","3060"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，国内人血白蛋白批签发量为5285万瓶(+11%)","content_offset":["3083","3113"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5285万瓶","3101","3107"],"indicator_element":{"时间":["2019年","3083","3088"],"产品":["人血白蛋白","3091","3096"],"渠道":["国内","3089","3091"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，国内人血白蛋白批签发量为5285万瓶(+11%)","content_offset":["3083","3113"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11%","3108","3112"],"indicator_element":{"时间":["2019年","3083","3088"],"产品":["人血白蛋白","3091","3096"],"渠道":["国内","3089","3091"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中国产批签发为2120万瓶(+13%)","content_offset":["3127","3147"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2120万瓶","3135","3141"],"indicator_element":{"时间":["2019年","3050","3055"],"产品":["人血白蛋白","3055","3060"],"渠道":["国产","3129","3131"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中国产批签发为2120万瓶(+13%)","content_offset":["3127","3147"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+13%","3142","3146"],"indicator_element":{"时间":["2019年","3050","3055"],"产品":["人血白蛋白","3055","3060"],"渠道":["国产","3129","3131"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"占比40%","content_offset":["3148","3153"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["40%","3150","3153"],"indicator_element":{"时间":["2019年","3050","3055"],"产品":["人血白蛋白","3055","3060"],"渠道":["国产","3129","3131"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"进口批签发为3165万瓶(+11%)","content_offset":["3154","3172"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3165万瓶","3160","3166"],"indicator_element":{"时间":["2019年","3083","3088"],"产品":["人血白蛋白","3055","3060"],"渠道":["进口","3154","3156"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"进口批签发为3165万瓶(+11%)","content_offset":["3154","3172"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+11%","3167","3171"],"indicator_element":{"时间":["2019年","3083","3088"],"产品":["人血白蛋白","3055","3060"],"渠道":["进口","3154","3156"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"占比60%","content_offset":["3173","3178"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["60%","3175","3178"],"indicator_element":{"时间":["2019年","3083","3088"],"产品":["人血白蛋白","3091","3096"],"渠道":["进口","3154","3156"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，国内人血白蛋白批签发量为3081万瓶(+35%)","content_offset":["3180","3211"],"indicators":[{"indicator_name":"批签发量","indicator_value":["3081万瓶","3199","3205"],"indicator_element":{"时间":["2020H1","3180","3186"],"产品":["人血白蛋白","3189","3194"],"区域":["国内","3187","3189"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，国内人血白蛋白批签发量为3081万瓶(+35%)","content_offset":["3180","3211"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+35%","3206","3210"],"indicator_element":{"时间":["2020H1","3180","3186"],"产品":["人血白蛋白","3189","3194"],"区域":["国内","3187","3189"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中进口人血白蛋白批签发量为2029万瓶(占比66%)","content_offset":["3212","3239"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2029万瓶","3226","3232"],"indicator_element":{"时间":["2020H1","3180","3186"],"产品":["人血白蛋白","3216","3221"],"区域":["国内","3187","3189"],"渠道":["进口","3214","3216"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中进口人血白蛋白批签发量为2029万瓶(占比66%)","content_offset":["3212","3239"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["66%","3235","3238"],"indicator_element":{"时间":["2020H1","3180","3186"],"产品":["人血白蛋白","3216","3221"],"区域":["国内","3187","3189"],"渠道":["进口","3214","3216"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q1人血白蛋白批签发量为1612万瓶(+83%)","content_offset":["3240","3264"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1612万瓶","3252","3258"],"indicator_element":{"时间":["Q1","3240","3242"],"产品":["人血白蛋白","3242","3247"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q1人血白蛋白批签发量为1612万瓶(+83%)","content_offset":["3240","3264"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+83%","3259","3263"],"indicator_element":{"时间":["Q1","3240","3242"],"产品":["人血白蛋白","3242","3247"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"进口人血白蛋白批签发量2007年-2019年CAGR(年均复合增长率)为+34%","content_offset":["4135","4175"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+34%","4171","4175"],"indicator_element":{"时间":["2007年-2019年","4146","4157"],"产品":["人血白蛋白","4137","4142"],"渠道":["进口","4135","4137"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1进口人血白蛋白批签发量为2029万瓶(+58%)","content_offset":["4330","4360"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2029万瓶","4348","4354"],"indicator_element":{"时间":["2020H1","4330","4336"],"产品":["人血白蛋白","4338","4343"],"渠道":["进口","4336","4338"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1进口人血白蛋白批签发量为2029万瓶(+58%)","content_offset":["4330","4360"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+58%","4355","4359"],"indicator_element":{"时间":["2020H1","4330","4336"],"产品":["人血白蛋白","4338","4343"],"渠道":["进口","4336","4338"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"市场份额66%","content_offset":["4361","4368"],"indicators":[{"indicator_name":"市占率","indicator_value":["66%","4365","4368"],"indicator_element":{"时间":["2020H1","4330","4336"],"产品":["人血白蛋白","4338","4343"],"渠道":["进口","4269","4271"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q1进口人血白蛋白批签发量为1069万瓶(+175%)","content_offset":["4409","4440"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1069万瓶","4427","4433"],"indicator_element":{"时间":["2020Q1","4409","4415"],"产品":["人血白蛋白","4417","4422"],"渠道":["进口","4415","4417"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q1进口人血白蛋白批签发量为1069万瓶(+175%)","content_offset":["4409","4440"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+175%","4434","4439"],"indicator_element":{"时间":["2020Q1","4409","4415"],"产品":["人血白蛋白","4417","4422"],"渠道":["进口","4415","4417"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q2进口批签发量为961万瓶(+7%)","content_offset":["4441","4460"],"indicators":[{"indicator_name":"批签发量","indicator_value":["961万瓶","4450","4455"],"indicator_element":{"时间":["Q2","4441","4443"],"产品":["人血白蛋白","4417","4422"],"渠道":["进口","4443","4445"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q2进口批签发量为961万瓶(+7%)","content_offset":["4441","4460"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+7%","4456","4459"],"indicator_element":{"时间":["Q2","4441","4443"],"产品":["人血白蛋白","4417","4422"],"渠道":["进口","4443","4445"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"国产人血白蛋白批签发量2007-2019年CAGR为+16%","content_offset":["5901","5931"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+16%","5927","5931"],"indicator_element":{"时间":["2007-2019年","5912","5922"],"产品":["人血白蛋白","5903","5908"],"渠道":["国产","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1国产批签发量为1051万瓶(+6%)","content_offset":["5948","5972"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1051万瓶","5961","5967"],"indicator_element":{"时间":["2020H1","5948","5954"],"产品":["人血白蛋白","5856","5861"],"渠道":["国产","5954","5956"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1国产批签发量为1051万瓶(+6%)","content_offset":["5948","5972"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+6%","5968","5971"],"indicator_element":{"时间":["2020H1","5948","5954"],"产品":["人血白蛋白","5856","5861"],"渠道":["国产","5954","5956"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"占国内人血白蛋白批签发的34%","content_offset":["5973","5988"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["34%","5985","5988"],"indicator_element":{"时间":["2020H1","5948","5954"],"产品":["人血白蛋白","5976","5981"],"渠道":["国产","5901","5903"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中Q1国产人血白蛋白批签发量为500万瓶(+10%)","content_offset":["5989","6016"],"indicators":[{"indicator_name":"批签发量","indicator_value":["500万瓶","6005","6010"],"indicator_element":{"时间":["Q1","5991","5993"],"产品":["人血白蛋白","5995","6000"],"渠道":["国产","5993","5995"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中Q1国产人血白蛋白批签发量为500万瓶(+10%)","content_offset":["5989","6016"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+10%","6011","6015"],"indicator_element":{"时间":["Q1","5991","5993"],"产品":["人血白蛋白","5995","6000"],"渠道":["国产","5993","5995"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q2批签发量为543万瓶(+3%)","content_offset":["6017","6034"],"indicators":[{"indicator_name":"批签发量","indicator_value":["543万瓶","6024","6029"],"indicator_element":{"时间":["Q2","6017","6019"],"产品":["人血白蛋白","5976","5981"],"渠道":["国产","5954","5956"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q2批签发量为543万瓶(+3%)","content_offset":["6017","6034"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+3%","6030","6033"],"indicator_element":{"时间":["Q2","6017","6019"],"产品":["人血白蛋白","5976","5981"],"渠道":["国产","5954","5956"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"静丙批签发量2007-2019年CAGR为+17%","content_offset":["7501","7526"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+17%","7522","7526"],"indicator_element":{"时间":["2007-2019年","7507","7517"],"产品":["静丙","7501","7503"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，国内静丙批签发量为1184万瓶(换算成2.5g/瓶，下同","content_offset":["7544","7578"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1184万瓶","7559","7565"],"indicator_element":{"时间":["2019年","7544","7549"],"产品":["静丙","7552","7554"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长12%","content_offset":["7580","7587"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["12%","7584","7587"],"indicator_element":{"时间":["2019年","7512","7517"],"产品":["静丙","7501","7503"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，静丙批签发量为705万瓶","content_offset":["7588","7607"],"indicators":[{"indicator_name":"批签发量","indicator_value":["705万瓶","7602","7607"],"indicator_element":{"时间":["2020H1","7588","7594"],"产品":["静丙","7595","7597"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长50%","content_offset":["261","268"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["50%","265","268"],"indicator_element":{"时间":["2020H1","187","193"],"产品":["静丙","248","250"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中Q1批签发为456万瓶(+97%)","content_offset":["7616","7635"],"indicators":[{"indicator_name":"批签发量","indicator_value":["456万瓶","7624","7629"],"indicator_element":{"时间":["Q1","7618","7620"],"产品":["静丙","7552","7554"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"其中Q1批签发为456万瓶(+97%)","content_offset":["7616","7635"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+97%","7630","7634"],"indicator_element":{"时间":["Q1","7618","7620"],"产品":["静丙","7552","7554"]},"indicator_supplement":{"属性":""}}]},{"id":"54","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q2国产批发量为249万瓶(+5%)","content_offset":["7636","7654"],"indicators":[{"indicator_name":"批签发量","indicator_value":["249万瓶","7644","7649"],"indicator_element":{"产品":["静丙","7552","7554"]},"indicator_supplement":{"属性":""}}]},{"id":"55","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"Q2国产批发量为249万瓶(+5%)","content_offset":["7636","7654"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+5%","7650","7653"],"indicator_element":{"产品":["静丙","7552","7554"]},"indicator_supplement":{"属性":""}}]},{"id":"56","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"免疫球蛋白批签发量2008-2019复合增长率(CAGR)为+2%","content_offset":["9142","9175"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+2%","9172","9175"],"indicator_element":{"产品":["免疫球蛋白","9142","9147"]},"indicator_supplement":{"属性":""}}]},{"id":"57","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，免疫球蛋白批签发为262万瓶(换算成150mg/瓶，下同)","content_offset":["9233","9268"],"indicators":[{"indicator_name":"批签发量","indicator_value":["262万瓶","9248","9253"],"indicator_element":{"产品":["免疫球蛋白","9239","9244"]},"indicator_supplement":{"属性":""}}]},{"id":"58","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长105%","content_offset":["9269","9277"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["105%","9273","9277"],"indicator_element":{"产品":["免疫球蛋白","9176","9181"]},"indicator_supplement":{"属性":""}}]},{"id":"59","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，免疫球蛋白批签发为174万瓶","content_offset":["9278","9299"],"indicators":[{"indicator_name":"批签发量","indicator_value":["174万瓶","9294","9299"],"indicator_element":{"产品":["免疫球蛋白","9285","9290"]},"indicator_supplement":{"属性":""}}]},{"id":"60","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长258%","content_offset":["9300","9308"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["258%","9304","9308"],"indicator_element":{"产品":["免疫球蛋白","9239","9244"]},"indicator_supplement":{"属性":""}}]},{"id":"61","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，免疫球蛋白批签发为51万瓶","content_offset":["9309","9329"],"indicators":[{"indicator_name":"批签发量","indicator_value":["51万瓶","9325","9329"],"indicator_element":{"产品":["免疫球蛋白","9316","9321"]},"indicator_supplement":{"属性":""}}]},{"id":"62","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"狂犬病免疫球蛋白批签发量2008-2019复合年均增长率(CAGR)为+19%","content_offset":["10575","10614"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+19%","10610","10614"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10575","10583"]},"indicator_supplement":{"属性":""}}]},{"id":"63","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，狂犬病免疫球蛋白批签发为1220万瓶","content_offset":["10634","10658"],"indicators":[{"indicator_name":"批签发量","indicator_value":["1220万瓶","10652","10658"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10640","10648"]},"indicator_supplement":{"属性":""}}]},{"id":"64","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长31%","content_offset":["10674","10681"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["31%","10678","10681"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10575","10583"]},"indicator_supplement":{"属性":""}}]},{"id":"65","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，狂犬病免疫球蛋白批签发为566万瓶","content_offset":["10682","10706"],"indicators":[{"indicator_name":"批签发量","indicator_value":["566万瓶","10701","10706"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10689","10697"]},"indicator_supplement":{"属性":""}}]},{"id":"66","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长21%","content_offset":["10707","10714"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["21%","10711","10714"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10640","10648"]},"indicator_supplement":{"属性":""}}]},{"id":"67","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，狂犬病免疫球蛋白批签发为306万瓶","content_offset":["10715","10739"],"indicators":[{"indicator_name":"批签发量","indicator_value":["306万瓶","10734","10739"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10722","10730"]},"indicator_supplement":{"属性":""}}]},{"id":"68","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长8%","content_offset":["10740","10746"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["8%","10744","10746"],"indicator_element":{"产品":["狂犬病免疫球蛋白","10640","10648"]},"indicator_supplement":{"属性":""}}]},{"id":"69","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"破伤风免疫球蛋白批签发量2008-2019年复合年均增长率(CAGR)为+12%","content_offset":["12179","12219"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+12%","12215","12219"],"indicator_element":{"产品":["破伤风免疫球蛋白","12179","12187"]},"indicator_supplement":{"属性":""}}]},{"id":"70","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，破伤风免疫球蛋白批签发为640万瓶","content_offset":["12249","12272"],"indicators":[{"indicator_name":"批签发量","indicator_value":["640万瓶","12267","12272"],"indicator_element":{"产品":["破伤风免疫球蛋白","12255","12263"]},"indicator_supplement":{"属性":""}}]},{"id":"71","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长80%","content_offset":["12285","12292"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["","12285","12285"],"indicator_element":{"产品":["破伤风免疫球蛋白","12224","12232"]},"indicator_supplement":{"属性":""}}]},{"id":"72","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，破伤风免疫球蛋白批签发为293万瓶(+12%)","content_offset":["12327","12357"],"indicators":[{"indicator_name":"批签发量","indicator_value":["293万瓶","12346","12351"],"indicator_element":{"产品":["破伤风免疫球蛋白","12334","12342"]},"indicator_supplement":{"属性":""}}]},{"id":"73","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，破伤风免疫球蛋白批签发为293万瓶(+12%)","content_offset":["12327","12357"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+12%","12352","12356"],"indicator_element":{"产品":["破伤风免疫球蛋白","12334","12342"]},"indicator_supplement":{"属性":""}}]},{"id":"74","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q1，破伤风免疫球蛋白批签发162万瓶","content_offset":["12358","12381"],"indicators":[{"indicator_name":"批签发量","indicator_value":["162万瓶","12376","12381"],"indicator_element":{"产品":["破伤风免疫球蛋白","12365","12373"]},"indicator_supplement":{"属性":""}}]},{"id":"75","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比上升28%","content_offset":["12382","12389"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["28%","12386","12389"],"indicator_element":{"产品":["破伤风免疫球蛋白","12334","12342"]},"indicator_supplement":{"属性":""}}]},{"id":"76","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，破伤风免疫球蛋白批签发131万瓶","content_offset":["12390","12413"],"indicators":[{"indicator_name":"批签发量","indicator_value":["131万瓶","12408","12413"],"indicator_element":{"产品":["破伤风免疫球蛋白","12397","12405"]},"indicator_supplement":{"属性":""}}]},{"id":"77","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比下降3%","content_offset":["12414","12420"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降3%","12416","12420"],"indicator_element":{"产品":["破伤风免疫球蛋白","12334","12342"]},"indicator_supplement":{"属性":""}}]},{"id":"78","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"乙肝免疫球蛋白2007-2019复合增长率(CAGR)为-1%","content_offset":["13630","13661"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["-1%","13658","13661"],"indicator_element":{"产品":["乙肝免疫球蛋白","13630","13637"]},"indicator_supplement":{"属性":""}}]},{"id":"79","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，乙肝免疫球蛋白批签发为220万瓶","content_offset":["13663","13685"],"indicators":[{"indicator_name":"批签发量","indicator_value":["220万瓶","13680","13685"],"indicator_element":{"产品":["乙肝免疫球蛋白","13669","13676"]},"indicator_supplement":{"属性":""}}]},{"id":"80","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比下滑31%","content_offset":["13701","13708"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下滑31%","13703","13708"],"indicator_element":{"产品":["乙肝免疫球蛋白","13630","13637"]},"indicator_supplement":{"属性":""}}]},{"id":"81","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，乙肝免疫球蛋白批签发为116万瓶","content_offset":["13709","13732"],"indicators":[{"indicator_name":"批签发量","indicator_value":["116万瓶","13727","13732"],"indicator_element":{"产品":["乙肝免疫球蛋白","13716","13723"]},"indicator_supplement":{"属性":""}}]},{"id":"82","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长7%","content_offset":["13733","13739"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["7%","13737","13739"],"indicator_element":{"产品":["乙肝免疫球蛋白","13669","13676"]},"indicator_supplement":{"属性":""}}]},{"id":"83","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q1，同比增长205%","content_offset":["13740","13755"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["205%","13751","13755"],"indicator_element":{"产品":["乙肝免疫球蛋白白","-1","-1"]},"indicator_supplement":{"属性":""}}]},{"id":"84","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，乙肝免疫球蛋白批签发量为76万瓶","content_offset":["13788","13811"],"indicators":[{"indicator_name":"批签发量","indicator_value":["76万瓶","13807","13811"],"indicator_element":{"产品":["乙肝免疫球蛋白","13795","13802"]},"indicator_supplement":{"属性":""}}]},{"id":"85","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比下降20%","content_offset":["13812","13819"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降20%","13814","13819"],"indicator_element":{"产品":["乙肝免疫球蛋白","13716","13723"]},"indicator_supplement":{"属性":""}}]},{"id":"86","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"凝血酶原复合物批签发2008-2019年CAGR为+28%","content_offset":["14971","15000"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+28%","14996","15000"],"indicator_element":{"产品":["凝血酶原复合物","14971","14978"]},"indicator_supplement":{"属性":""}}]},{"id":"87","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，凝血酶原复合物批签发为102万瓶","content_offset":["15066","15088"],"indicators":[{"indicator_name":"批签发量","indicator_value":["102万瓶","15083","15088"],"indicator_element":{"产品":["凝血酶原复合物","15072","15079"]},"indicator_supplement":{"属性":""}}]},{"id":"88","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长3%","content_offset":["15104","15110"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["3%","15108","15110"],"indicator_element":{"产品":["凝血酶原复合物","15072","15079"]},"indicator_supplement":{"属性":""}}]},{"id":"89","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1凝血酶原复合物批签量发为81万瓶(+111%)","content_offset":["15111","15140"],"indicators":[{"indicator_name":"批签发量","indicator_value":["81万瓶","15129","15133"],"indicator_element":{"产品":["凝血酶原复合物","15117","15124"]},"indicator_supplement":{"属性":""}}]},{"id":"90","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1凝血酶原复合物批签量发为81万瓶(+111%)","content_offset":["15111","15140"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+111%","15134","15139"],"indicator_element":{"产品":["凝血酶原复合物","15117","15124"]},"indicator_supplement":{"属性":""}}]},{"id":"91","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"凝血因子VIII行业2008-2019年CAGR为-2%","content_offset":["15675","15703"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["-2%","15700","15703"],"indicator_element":{"产品":["凝血因子Ⅷ","15631","15636"]},"indicator_supplement":{"属性":""}}]},{"id":"92","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年，凝血因子Ⅷ批签发为181万瓶(转换为200IU/瓶，下同)","content_offset":["15717","15752"],"indicators":[{"indicator_name":"批签发量","indicator_value":["181万瓶","15732","15737"],"indicator_element":{"产品":["凝血因子Ⅷ","15723","15728"]},"indicator_supplement":{"属性":""}}]},{"id":"93","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比增长8%","content_offset":["10740","10746"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["8%","10744","10746"],"indicator_element":{"产品":["凝血因子Ⅷ","15631","15636"]},"indicator_supplement":{"属性":""}}]},{"id":"94","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，凝血因子Ⅷ批签发为101万瓶(+32%)","content_offset":["15761","15788"],"indicators":[{"indicator_name":"批签发量","indicator_value":["101万瓶","15777","15782"],"indicator_element":{"产品":["凝血因子Ⅷ","15768","15773"]},"indicator_supplement":{"属性":""}}]},{"id":"95","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，凝血因子Ⅷ批签发为101万瓶(+32%)","content_offset":["15761","15788"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+32%","15783","15787"],"indicator_element":{"产品":["凝血因子Ⅷ","15768","15773"]},"indicator_supplement":{"属性":""}}]},{"id":"96","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，凝血因子Ⅷ批签发为41万瓶(+20%)","content_offset":["15796","15822"],"indicators":[{"indicator_name":"批签发量","indicator_value":["41万","15812","15815"],"indicator_element":{"产品":["凝血因子Ⅷ","15803","15808"]},"indicator_supplement":{"属性":""}}]},{"id":"97","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，凝血因子Ⅷ批签发为41万瓶(+20%)","content_offset":["15796","15822"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["+20%","15817","15821"],"indicator_element":{"产品":["凝血因子Ⅷ","15803","15808"]},"indicator_supplement":{"属性":""}}]},{"id":"98","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"纤维蛋白原2008-2019年CAGR为+49%","content_offset":["16875","16899"],"indicators":[{"indicator_name":"批签发量年复合增长率","indicator_value":["+49%","16895","16899"],"indicator_element":{"产品":["纤维蛋白原","16875","16880"]},"indicator_supplement":{"属性":""}}]},{"id":"99","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2019年纤维蛋白原批签发为89万瓶(0.5g/瓶，下同)","content_offset":["16913","16942"],"indicators":[{"indicator_name":"批签发量","indicator_value":["89万瓶","16927","16931"],"indicator_element":{"产品":["纤维蛋白原","16918","16923"]},"indicator_supplement":{"属性":""}}]},{"id":"100","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020H1，纤维蛋白原批签发为62万瓶","content_offset":["16954","16974"],"indicators":[{"indicator_name":"批签发量","indicator_value":["62万瓶","16970","16974"],"indicator_element":{"产品":["纤维蛋白原","16961","16966"]},"indicator_supplement":{"属性":""}}]},{"id":"101","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比上升38%","content_offset":["16975","16982"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["38%","16979","16982"],"indicator_element":{"产品":["纤维蛋白原","16875","16880"]},"indicator_supplement":{"属性":""}}]},{"id":"102","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"2020Q2，纤维蛋白原批签发为35万瓶","content_offset":["16983","17003"],"indicators":[{"indicator_name":"批签发量","indicator_value":["35万瓶","16999","17003"],"indicator_element":{"产品":["纤维蛋白原","16990","16995"]},"indicator_supplement":{"属性":""}}]},{"id":"103","source_document":"2020年H1血制品批签发：多数品种增长较好.pdf","content":"同比上升126%","content_offset":["17004","17012"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["126%","17008","17012"],"indicator_element":{"产品":["纤维蛋白原","16918","16923"]},"indicator_supplement":{"属性":""}}]}]}